Progenics Pharmaceuticals, Inc. company was founded in 1986 and is based in Tarrytown, New York. Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases in the United States and internationally. The company, in collaboration with Wyeth Pharmaceuticals, provides RELISTOR-Subcutaneous injection for the treatment of opioid-induced constipation (OIC) in advanced illness patients receiving palliative care. It is also developing the HIV entry inhibitor, PRO 140, a humanized monoclonal antibody targeting the entry co-receptor, CCR5, and is in Phase II clinical testing; and a novel HCV entry inhibitor, PRO 206. In addition, Progenics Pharmaceuticals is conducting a Phase I clinical trial of a human monoclonal antibody-drug conjugate (ADC) designed to selectively target prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells, as well as in blood vessels supplying non-prostatic solid tumors; and various Phase I clinical trials with vaccines designed to treat prostate cancer by stimulating an immune response to PSMA.

Peoplesway.Com, Inc., an electronic commerce and Internet services company, maintains an Internet destination called ‘Peoplesway’, located at www.peoplesway.com. The majority of the company’s goods and services are available through an alliance with DRM, Inc. and its member network of approximately 14,000 independent contractors. The Web site offers goods and services for sale, such as personal hygiene products, skin care, hair care, and bath products. In addition, DRM supplies Body Management System nutritional products, including weight loss and anti-aging supplements. DRM manufactures and packages these products through a licensing agreement with a health and beauty product manufacturer.

Spectrum Pharmaceuticals, Inc. operates as a commercial-stage biotechnology company with a primary focus in oncology market. The company focuses on acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products. Its marketed products include ZEVALIN, a form of cancer therapy called radioimmunotherapy for the treatment of non-Hodgkin's Lymphoma; and FUSILEV, which is indicated after high-dose methotrexate therapy in patients with osteosarcoma. The company also develops apaziquone for the treatment of non-muscle invasive bladder cancer. Its phase II products comprise Ozarelix, a drug being investigated for benign prostatic hypertrophy, a non-cancerous enlargement of the prostate; and Ortataxel, a third-generation taxane. In addition, Spectrum Pharmaceuticals, Inc. has exclusive worldwide rights to Renazorb, Renalan, and related compounds. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Irvine, California.

Lescarden Inc. was founded in 1960 and is based in New York, New York. Lescarden Inc. engages in the research, testing, and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis, and cancer applications. The company offers CATRIX Wound Dressing, a powder derived from bovine cartilage for the management of chronic lesions and burns, as well as for non-healing wounds, such as decubitus ulcers, venous stasis ulcers, and diabetic ulcers. It also provides a line of Catrix-based skin care products for the plastic surgery, dermatology, and medical spa markets. In addition, the company offers nutritional supplements, including BIO-CARTILAGE; and POLY-Nag, a glucosamine polymer for the treatment of osteoarthritis. It also licenses its technologies for commercialization by other companies in Canada, Europe, and Korea. The company sells its products primarily in Europe, the Philippines, and Korea.

Endo Pharmaceuticals Holdings Inc. was founded in 1997 and is headquartered in Chadds Ford, Pennsylvania. Endo Pharmaceuticals Holdings Inc., a pharmaceutical company, engages in the research, development, sale, and marketing of branded and generic prescription pharmaceuticals for treating and managing pain primarily in the United States. Its products include Lidoderm, a topical patch product for the relief of the pain associated with post-herpetic neuralgia; Opana ER and Opana for the relief of moderate-to-severe pain in patients; Percocet and Percodan tablets; Frova for the treatment of migraine headaches in adults; and Voltaren Gel for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company's products also include Sanctura for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Sanctura XR to treat OAB symptoms; Supprelin LA for treating central precocious puberty (CPP) or the early onset of puberty in children; Vantas provides histrelin, a luteinizing hormone-releasing hormone (LHRH) agonist, for the palliative treatment of advanced prostate cancer; Delatestryl for the treatment of male hypogonadism; Hydron Implant; and Valstar, a sterile solution of valrubicin for intravesical instillation. Its development stage products include Nebido for treatment of hypogonadisml; PRO 2000, a Phase III clinical stage product for the prevention of infection by HIV and other sexually-transmitted pathogens; octreotide implant, a Phase III clinical stage product for the treatment of acromegaly; and axomadol, a Phase II clinical stage product for the treatment of moderate to moderately severe chronic pain and diabetic peripheral neuropathic pain. The company's generic products include Morphine Sulfate and Endocet, an oxycodone hydrochloride and acetaminophen product. It has strategic alliances with Novartis AG, Hind Healthcare, Penwest Pharmaceuticals Co., and Vernalis Development Limited.

Third Wave Technologies is riding the biotech breakers. Using its Invader technology, Third Wave develops molecular diagnostic tests that detect genetic variations associated with a variety of conditions, including cystic fibrosis, cardiovascular risk factors, and infectious disease. Some tests can determine a patient's likely response to certain drugs, making it possible for doctors to avoid prescribing a drug that might cause dangerous side effects. Third Wave company has a strong presence in Japan, where it has a collaboration agreement with genetic researchers at the University of Tokyo. Third Wave Technologies was acquired by Hologic in 2008 for $580 million.

diaDexus, Inc. was founded in 1997 and is based in South San Francisco, California. diaDexus, Inc., a biotechnology company, engages in the discovery, development, and commercialization of in vitro diagnostic products to address the medical needs in the cardiovascular field. The company develops The PLAC Test, a blood test to aid in assessing risk for coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis. Its product measures lipoprotein-associated phospholipase A2 (Lp-PLA2), which is a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. The company’s PLAC Test is available as an ELISA assay that runs on an automated micropate system, as well as in the form of immunotarbidimetric technology that runs on common clinical chemistry analyzers used in clinical reference laboratories, hospitals, and physician office laboratories.

Pfizer Inc. company was founded in 1849 and is headquartered in New York, New York. Pfizer Inc. (Pfizer) is a research-based, global pharmaceutical company. The Company discovers, develops, manufactures and markets prescription medicines for humans and animals. It operates in two business segments: Pharmaceutical and Animal Health. Pfizer also operates several other businesses, including the manufacture of gelatin capsules, contract manufacturing and bulk pharmaceutical chemicals. In June 2008, Pfizer completed the acquisition of all remaining outstanding shares of common stock of Encysive Pharmaceuticals, Inc. through a merger of Pfizer's wholly owned subsidiary, Explorer Acquisition Corp., with and into Encysive. In July 2009, Pfizer bought back a 29.52% stake in its Indian arm, Pfizer Limited, increasing its stake to 70.75%.In October 2009, Pfizer Inc. acquired Wyeth. In December 2009, Durata Therapeutics, Inc. acquired Vicuron Pharmaceuticals from Pfizer.

EastPharma would like to be the place where east meets west. The Turkish pharmaceutical manufacturer operates via two major subsidiaries. Deva Holdings makes branded generics, active pharmaceutical ingredients (API), veterinary products, and consumer hygiene products. Its Saba unit makes generic high-end cardiovascular and pain medications. EastPharma sells about 70 branded generics and a dozen licensed drugs including versions of the blockbuster drugs Viagra, Singulair, and Lamisil. The company operates seven manufacturing plants in and around Istanbul and sell its products in nearly 20 Eastern European countries with an eye toward Western expansion.

United Research Laboratories (URL), along with sister company Mutual Pharmaceutical (together known as URL/Mutual), manufactures generic medications and conducts research on existing drug formulas through agreements with other pharmaceutical companies. URL/Mutual has developed generic versions of drugs manufactured by King, Ortho-McNeil, Merck, and Berlex, among others. The company has also developed its own proprietary drug delivery systems. URL and Mutual Pharmaceuticals are subsidiaries of URL Pharma (formerly Pharmaceutical Holdings Corporation).

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.